EMOKSIBEL | Certus

EMOKSIBEL

PHARMACOLOGICAL EFFECT:

PHARMACODYNAMICS: Emoxypinumreduces symptoms of cerebral hemo-dysfunction. Increases the resistance of the brain to hypoxia and ischemia. During cerebral blood circulation (ischemic and hemorrhagic) helps to the correction of vegetative dysfunctions, enfolds the recovery of the integrative activity of the brain, and improves the mnemonic function. Has hypolipidemic effect, reduces triglyceride synthesis.

The medication has a strong cardio protective effect. Dilates coronary vessels, reduces myocardial ischemic injury. During myocardial infarction limits the amount of necrosis, accelerates the recovery processes, and contributes to the normalization of myocardial metabolism. Has a beneficial effect on the clinical course of myocardial infarction, reducing the incidence of congestive heart failure. Helps to regulate the redox system during insufficiency of the blood circulation.

Emoxypinum has a beneficial effect on the blood coagulation system: inhibits platelet aggregation, reduces the overall coagulation index, prolongs the clotting time of blood. Stabilizes the cell membranes of blood vessels and red blood cells, increases the resistance of red blood cells to mechanical trauma and hemolysis. It possesses angioprotective properties and improves the microcirculation.

Effectively inhibits free radical oxidation of lipids of membranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has antitoxic effect.

Protects the retina from the damaging effects of high-intensity light, contributes to the resorption of intraocular hemorrhage.

PHARMACOKINETICS:

When administered intravenously at a dose of 10 mg/ml there was observed low elimination half-life. T1/2 is 18 min. The total clearance Cl is 214.8 ml/min. The medication quickly penetrates into the organs and tissues, where it is being deposited and metabolized. There are 5 metabolites of emoxypinum presented as dealkylation and conjugation products of its transformation. Under pathological conditions, for example in the case of coronary occlusion the pharmacokynetics of emoxipynum varies. The speed of excretion is reduced, thereby increasing the bioavailability of the medication.

During retrobulbar administration of emoxipynum it is almost instantly appearing in blood; during the first two hours, it’s concentration decreases rapidly and after 24 hours it is being absent in the blood. In ocular tissue the concentration of emoxipynum is higher than in the blood.

INDICATIONS:

In Neurology and Neurosurgery: hemorrhagic stroke, ischemic stroke in the pool of the internal carotid artery and in the vertebra-basilar system, transient disorders of the cerebrovascular blood circulation, chronic insufficiency of the cerebrovascular blood circulation , craniocerebral injury accompanied by injuries of the brain; the postoperative period in patients with craniocerebral injury, operated on for epi-, subdural and intracerebral hematomas, combined with injuries of the brain; the pre-and postoperative period in patients with arterial aneurysms and arteriovenous malformations of the brain vessels.

In cardiology: acute myocardial infarction, prevention of "Reperfusion Syndrome", unstable angina pectoris.

In surgery: acute and chronic pancreatitis, pseudo tumor pancreatitis, peritonitis, pre-and postoperative period in patients with chronic pancreatitis.

DOSAGE:

In neurology: the emoxipynum solution for infusion is administered intravenously in drip form at a daily dose of 5 - 10 mg/kg (100 -200 ml), during 10-12 days. It is administered in a speed of 20-30 drops per minute.

In cardiology: it is started from the intravenous drip (20-40 drops per minute) injection of 100 -200 ml of the medication (500-1.000 mg of emoxipynum) 1-3 times per a day, during 5-15 days depending on the disease.

In Surgery: in patients with acute and chronic pancreatitis in the acute stage, during peritonitis, before and after deep X-ray therapy, during pseudo tumor pancreatitis, during obstructive jaundice of various origins, as well as during pre-and postoperative period in patients operated on organs hepato-pancreato-duodenalzone it is administered at a dose of 30 mlintravenously (20-40 drops per minute), 2 times per a day, during 10-15 days.

It is necessary in the course of treatment to constantly monitor blood pressure and indicators.

CONTRAINDICATIONS:

The use of the drug is contraindicated for those who are hypersensitive and pregnant.

SIDE EFFECTS:

Local reactions at injection site (transient feeling of burn, itching, pain), high blood pressure, excitation (short-term), drowsiness, headache, chest pain, allergic reactions (itching, rash, redness of the skin), nausea, discomfort in the stomach.

SPECIAL INSTRUCTIONS:

During the course of treatment, it is recommended to temporarily stop such work activities that require attention.

PRECAUTIONS:

During the lactation, the drug can be used by women in accordance with the instruction. Treatment should be passed under the control of blood pressure and blood clotting. Do not mix the solution of the emoxipynum with other medications.

RELEASE FORM:

0,5% solution for infusion, in vials of 100 ml.